Table 1.

Comparison of the frequencies of biomarkers for immunotherapy in the Chinese population with those of Western populations and TCGA data

TMB (NSM)		Reference26, 27
Pancreatic carcinoma	51	Pancreatic adenocarcinoma	45
Breast carcinoma	66	Breast carcinoma	33
Gastric carcinoma	66	Stomach adenocarcinoma	179
Glioma	77	Glioma	31
Cervical carcinoma	88	Cervical squamous cell carcinoma	46
Renal cell carcinoma	94	Renal cell carcinoma	38
Hepatocellular carcinoma	106	Hepatocellular carcinoma	39
Colorectal Carcinoma	108	Colon cancer	315
Esophageal carcinoma	120	Esophageal carcinoma	75
Lung squamous cell carcinoma	273	Lung squamous cell carcinoma	175
Lung adenocarcinoma	74	Lung adenocarcinoma	155

MSI‐H (%)		Reference28
Colorectal Carcinoma	8.30	Colorectal Carcinoma	13
Gastric carcinoma	2.30	Gastric carcinoma	22
Lung cancer	0.40	Lung cancer	2
Breast carcinoma	0.66	Breast carcinoma	1

dMMR (%)		Reference12
Gastric carcinoma	5.75	Gastric adenocarcinoma carcinoma	≈9
Breast carcinoma	6.62	Breast carcinoma	1
Hepatocellular carcinoma	3.03	Hepatocellular carcinoma	3
Colorectal Carcinoma	5.93	Colorectal adenocarcinoma	6
Esophageal carcinoma	4.35	Esophageal carcinoma	1
Non‐small cell lung cancer	5.14	Non‐small cell lung cancer	1

PD‐L1 amplification (%)		Reference29
Lung squamous cell carcinoma	14.29	Lung squamous cell carcinoma	>15
Sarcoma of soft tissue	6.06	Sarcoma	>15
Renal cell carcinoma	2.78	Renal clear carcinoma	<5
Lung adenocarcinoma	1.75	Lung adenocarcinoma	10‐15
Colorectal cancer	1.59	Colorectal adenocarcinoma	>15
Breast carcinoma	8.54	Breast invasive carcinoma	>15

Abbreviations: dMMR, DNA mismatch repair deficiency; MSI‐H, high MSI; NSM, nonsynonymous somatic mutations; TMB, tumor mutation burden.